Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
We Can Medicines CoROCO:6929 +0.89%55 EV-to-EBITDA is 7.16 as of Sep. 05, 2026, which is 24% below its 10-year median of 9.46. GuruFocus rates ROCO:6929 with a GF Score™ of 55/100 and a GF Value™ of NT$35.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,656 Consumer Packaged Goods companies, We Can Medicines Co ranks better than 65.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, We Can Medicines Co's enterprise value is NT$1,907 Mil.
We Can Medicines Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$266 Mil. Therefore, We Can Medicines Co's EV-to-EBITDA for today is 7.16.
The historical rank and industry rank for We Can Medicines Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6929'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.1 Med: 9.46 Max: 28.41
Current: 7.16
During the past 6 years, the highest EV-to-EBITDA of We Can Medicines Co was 28.41. The lowest was 7.10. And the median was 9.46.
ROCO:6929's EV-to-EBITDA is ranked better than 65.16% of 1656
companies
in the Consumer Packaged Goods industry
Industry Median: 9.24
vs ROCO:6929: 7.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
We Can Medicines Co (ROCO:6929) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
We Can Medicines Co's PE Ratio (TTM) for today is calculated as:
We Can Medicines Co's share price for today is NT$22.60.
We Can Medicines Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for We Can Medicines Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, We Can Medicines Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
We Can Medicines Co EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where We Can Medicines Co's EV-to-EBITDA falls into.
We Can Medicines Co's current Enterprise Value is NT$1,907 Mil.
We Can Medicines Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$266 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
We Can Medicines Co (ROCO:6929) has a EV-to-EBITDA of 7.16 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on We Can Medicines Co. This is 24% below median its historical median of 9.46. Over the past decade, We Can Medicines Co's EV-to-EBITDA has ranged from 7.10 to 28.41. According to the industry distribution chart, We Can Medicines Co ranks #577 out of 1656 companies in the Consumer Packaged Goods industry, placing it in the top 34.8%.
Is We Can Medicines Co's EV-to-EBITDA too high?
We Can Medicines Co's current EV-to-EBITDA of 7.16 is 24% below median its 10-year median of 9.46. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 28.41. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.24. We Can Medicines Co's value of 7.16 is 22.5% below this industry median. Based on the distribution chart, We Can Medicines Co ranks #577 out of 1656 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, We Can Medicines Co has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's EV-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, We Can Medicines Co ranks #577 out of 1656 companies for EV-to-EBITDA. This puts We Can Medicines Co in the upper half of its industry. The industry median EV-to-EBITDA is 9.24. We Can Medicines Co's value of 7.16 is 22.5% below this benchmark. Historically, We Can Medicines Co's own EV-to-EBITDA has ranged from 7.10 to 28.41 over the past decade. While the company's 10-year median is 9.46 vs. the industry median of 9.24, We Can Medicines Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.24, based on 1,656 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. We Can Medicines Co's current EV-to-EBITDA of 7.16 is 22.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on We Can Medicines Co. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. We Can Medicines Co's current EV-to-EBITDA is 7.16, which is 24% below median its own 10-year median of 9.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$35.51, compared to a current price of NT$22.60 — trading 36.4% below its estimated fair value. The current EV-to-EBITDA is 7.16, which is 24% below median its 10-year median of 9.46 and 22.5% below the Consumer Packaged Goods industry median of 9.24. We Can Medicines Co's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current EV-to-EBITDA is 7.16 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?
Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued.
The current stock price of NT$22.60 is trading 36.4% below its estimated GF Value™ of NT$35.51.
GuruFocus considers We Can Medicines Co to be Possible Value Trap.
Key valuation signals for ROCO:6929:
EV-to-EBITDA: 7.16 (24% below median its 10-year median of 9.46)
GF Value™: NT$35.51 vs. price of NT$22.60 (36.4% below fair value)
Industry Position: 22.5% below the Consumer Packaged Goods median (#577 of 1656)
No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
55GF Score
Get the complete analysis for ROCO:6929
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6929 has been successfully added to your 
